ELI-002 7P
A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.
Elicio's amphiphile peptides (7 mKRAS antigens) plus CpG adjuvant, engineered to drain to lymph nodes. Phase 1 AMPLIFY-201 induced mKRAS-specific T cells in most patients with ctDNA reductions. Randomised phase 2 AMPLIFY-7P (adjuvant PDAC, results June 2026) did not meet its primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses reported ~14% absolute DFS benefit during active treatment. Elicio is refining a phase 3 strategy around R0-resected patients.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"ELI-002 7P" OR ABSTRACT:"ELI-002 7P") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELI-002 7P, not a curated reading list.
Pages like this
not linked directly; found by shared links- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Off-the-shelf cancer vaccines, KRAS, The undruggable drivers, MRD / molecular residual disease testing.
- ProductMRTX1133
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductElironrasib
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- CompanyQuanta Therapeutics
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- CompanyFrontier Medicines
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares KRAS, The undruggable drivers, MRD / molecular residual disease testing, Pancreatic ductal adenocarcinoma.
- RoadmapKRAS roadmap: undruggable → G12C → pan-RAS
Shares Off-the-shelf cancer vaccines, KRAS, The undruggable drivers, Pancreatic ductal adenocarcinoma.